Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Note on target definition: The original query "CD206 and Toll-Like Receptors" improperly merges two distinct protein families; for structured annotation, these should be handled as individual targets, given their unique molecular, functional, and pharmacological characteristics. Their interaction is a subject of immunological research but they are not a single molecular entity. CD206 (Mannose receptor) is a type I transmembrane C-type lectin receptor found mainly on macrophages, dendritic cells, and endothelial cells. It binds terminal mannose, N-acetylglucosamine, and fucose residues on pathogens or glycoproteins, mediating their endocytosis and removal, and plays a regulatory role in innate and adaptive immunity. It is involved in immunosurveillance and tissue homeostasis, and high expression is observed in tissue pathology, notably in tumor-associated macrophages. Soluble forms of CD206 are shed in disease and serve as biomarkers. Toll-like receptors (TLRs) are a family of pattern recognition receptors critical for detecting microbial structures (PAMPs—pathogen-associated molecular patterns). They are classified by their specificity (TLR1-10 in humans), detect a wide range of microbial and host danger signals, and initiate downstream signaling pathways that drive both innate and adaptive immune responses. They are widely expressed in various immune and non-immune cells, and their signaling shapes T cell polarization, cytokine secretion, and the outcome of infections or inflammatory conditions.
For CD206: Ligand (mannose/complex glycans) binding triggers endocytosis/phagocytosis, promotes antigen uptake/presentation, mediates immune regulation; some drugs block ligand binding or modulate receptor recycling. For Toll-like receptors: Ligand (PAMP/DAMP) binding triggers downstream NF-κB and MAPK pathways, resulting in cytokine production and immune cell activation; some drugs act as agonists to boost immunity or antagonists to dampen inflammation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD206 and Toll-Like Receptors (CD206 and TLRs).